Active substance
Glimepiride
- SFDA 67
- US FDA 18
- Health Canada 3
- US price lines 3
- NHS prices 4
- Safety 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| AMAGLIME 1 mg tablet | 1 mg | Tablet · Oral use | 30 Blister | SAR 10.35 | Generic · Prescription | Middle East Pharmaceutical Industries Co Ltd Avalon Pharma | Valid |
| AMAGLIME 1 mg tablet | 1 mg | Tablet · Oral use | 60 Blister | SAR 16.70 | Generic · Prescription | Middle East Pharmaceutical Industries Co Ltd Avalon Pharma | Valid |
| AMAGLIME 2 mg tablet | 2 mg | Tablet · Oral use | 30 Blister | SAR 13.70 | Generic · Prescription | Middle East Pharmaceutical Industries Co Ltd Avalon Pharma | Valid |
| AMAGLIME 3 mg tablet | 3 mg | Tablet · Oral use | 30 Blister | SAR 23.60 | Generic · Prescription | Middle East Pharmaceutical Industries Co Ltd Avalon Pharma | Valid |
| AMAGLIME 3 mg tablet | 3 mg | Tablet · Oral use | 60 Blister | SAR 42.50 | Generic · Prescription | Middle East Pharmaceutical Industries Co Ltd Avalon Pharma | Valid |
| AMARYL 1MG TAB | 1 mg | Tablet · Oral use | 30 Blister | SAR 20.80 | NCE · Prescription | sanofi-aventis | Valid |
| AMARYL 2MG TAB | 2 mg | Tablet · Oral use | 30 Blister | SAR 33.90 | NCE · Prescription | sanofi-aventis | Valid |
| AMARYL 3MG TAB | 3 mg | Tablet · Oral use | 30 Blister | SAR 47.15 | NCE · Prescription | sanofi-aventis | Valid |
| AMARYL 6 mg tablet | 6 mg | Tablet · Oral use | 30 Blister | SAR 52.35 | Generic · Prescription | sanofi-aventis | Valid |
| Amaglime | 2 mg | Tablet · Oral use | 500 Blister | SAR 228.35 | Generic · Prescription | Middle East Pharmaceutical Industries Co Ltd Avalon Pharma | Valid |
| Amaglime | 2 mg | Tablet · Oral use | 500 Blister | SAR 228.35 | Generic · Prescription | Middle East Pharmaceutical Industries Co Ltd Avalon Pharma | Valid |
| G-PRIDE 1 mg tablet | 1 mg | Tablet · Oral use | 30 Blister | SAR 8.35 | Generic · Prescription | OMAN PHARMACEUTICAL PRODUCTS | Valid |
| G-PRIDE 2 mg tablet | 2 mg | Tablet · Oral use | 30 Blister | SAR 13.70 | Generic · Prescription | OMAN PHARMACEUTICAL PRODUCTS | Valid |
| G-PRIDE 3 mg tablet | 3 mg | Tablet · Oral use | 30 Blister | SAR 21.25 | Generic · Prescription | OMAN PHARMACEUTICAL PRODUCTS | Valid |
| G-PRIDE 4 mg tablet | 4 mg | Tablet · Oral use | 30 Blister | SAR 24.95 | Generic · Prescription | OMAN PHARMACEUTICAL PRODUCTS | Valid |
| GLEMAX 1 mg Tablet | 1 mg | Tablet · Oral use | 30 Blister | SAR 8.35 | Generic · Prescription | Jordan Sweden Medical and Sterilization Co. | Valid |
| GLEMAX 2 mg Tablet | 2 mg | Tablet · Oral use | 30 Blister | SAR 13.70 | Generic · Prescription | Jordan Sweden Medical and Sterilization Co. | Valid |
| GLEMAX 3 mg Tablet | 3 mg | Tablet · Oral use | 30 Blister | SAR 21.25 | Generic · Prescription | Jordan Sweden Medical and Sterilization Co. | Valid |
| GLEMAX 4 mg Tablet | 4 mg | Tablet · Oral use | 30 Blister | SAR 24.95 | Generic · Prescription | Jordan Sweden Medical and Sterilization Co. | Valid |
| GLEMAX 6 mg Tablet | 6 mg | Tablet · Oral use | 30 Blister | SAR 37.40 | Generic · Prescription | Jordan Sweden Medical and Sterilization Co. | Valid |
| GLIDE 1MG TABLET | 1 mg | Tablet · Oral use | 30 Blister | SAR 10.35 | Generic · Prescription | DEEF PHARMACEUTICAL INDUSTRIES | Valid |
| GLIDE 2MG TABLET | 2 mg | Tablet · Oral use | 30 Blister | SAR 13.70 | Generic · Prescription | DEEF PHARMACEUTICAL INDUSTRIES | Valid |
| GLIDE 3MG TABLET | 3 mg | Tablet · Oral use | 30 Blister | SAR 23.60 | Generic · Prescription | DEEF PHARMACEUTICAL INDUSTRIES | Valid |
| GLIDE 4MG TABLET | 4 mg | Tablet · Oral use | 30 Blister | SAR 24.95 | Generic · Prescription | DEEF PHARMACEUTICAL INDUSTRIES | Valid |
| GLIM 1MG TABLETS | 1 mg | Tablet · Oral use | 30 Blister | SAR 19.75 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
42 more — full table
Indications — CHI Daman Drug Formulary
DIABETES MELLITUS TYPE 2
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| GLIMEPIRIDE | 1MG; 2MG; 4MG | tablet · oral | DR REDDYS LABS LTD | Prescription | 6 Oct 2005 |
| GLIMEPIRIDE | 1MG; 2MG; 4MG | tablet · oral | CHARTWELL MOLECULAR | Prescription | 6 Oct 2005 |
| GLIMEPIRIDE | 1MG; 2MG; 4MG; 8MG | tablet · oral | PRINSTON INC | Prescription | 23 Dec 2005 |
| GLIMEPIRIDE | 1MG; 2MG; 4MG | tablet · oral | ACCORD HLTHCARE | Prescription | 23 Aug 2007 |
| GLIMEPIRIDE | 1MG; 2MG; 4MG | tablet · oral | CARLSBAD | Prescription | 22 Sep 2009 |
| GLIMEPIRIDE | 1MG; 2MG; 3MG; 4MG; 6MG; 8MG | tablet · oral | MICRO LABS | Prescription | 29 Jun 2012 |
| GLIMEPIRIDE | 1MG; 2MG; 4MG | tablet · oral | AUROBINDO PHARMA LTD | Prescription | 29 Jun 2012 |
| GLIMEPIRIDE | 1MG; 2MG; 4MG | tablet · oral | REGCON HOLDINGS | Prescription | 17 Apr 2013 |
| AMARYL | 1MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 2MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 4MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | SANOFI AVENTIS US | Discontinued | 30 Nov 1995 |
| GLIMEPIRIDE | 1MG; 2MG; 4MG | tablet · oral | SENORES PHARMS | Discontinued | 6 Oct 2005 |
| GLIMEPIRIDE | 1MG; 2MG; 4MG | tablet · oral | EPIC PHARMA LLC | Discontinued | 6 Oct 2005 |
| GLIMEPIRIDE | 3MG; 6MG | tablet · oral | RANBAXY | Discontinued | 6 Oct 2005 |
| GLIMEPIRIDE | 1MG; 2MG; 4MG | tablet · oral | QUAGEN | Discontinued | 28 Nov 2005 |
| GLIMEPIRIDE | 1MG; 2MG; 4MG | tablet · oral | WATSON LABS | Discontinued | 3 Feb 2006 |
| GLIMEPIRIDE | 1MG; 2MG; 4MG | tablet · oral | MYLAN | Discontinued | 10 Feb 2006 |
| GLIMEPIRIDE | 1MG; 2MG; 4MG | tablet · oral | ACTAVIS LABS FL INC | Discontinued | 26 Apr 2010 |
| GLIMEPIRIDE | 1MG; 2MG; 4MG | tablet · oral | HIKMA PHARMS | Discontinued | 1 Aug 2013 |
| GLIMEPIRIDE | 1MG; 2MG; 4MG; 8MG | tablet · oral | RANBAXY LABS LTD | Discontinued |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| SANDOZ GLIMEPIRIDE | 02269589 | 1 MG | TABLET · ORAL | SANDOZ CANADA INCORPORATED |
| SANDOZ GLIMEPIRIDE | 02269597 | 2 MG | TABLET · ORAL | SANDOZ CANADA INCORPORATED |
| SANDOZ GLIMEPIRIDE | 02269619 | 4 MG | TABLET · ORAL | SANDOZ CANADA INCORPORATED |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | GLIMEPIRIDE 1 MG TABLET | $0.02432 | per EA | 23 Sep 2026 |
| US NADAC | GLIMEPIRIDE 2 MG TABLET | $0.03752 | per EA | 23 Sep 2026 |
| US NADAC | GLIMEPIRIDE 4 MG TABLET | $0.05069 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Glimepiride 1mg tablets | £1.09 | 30 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Glimepiride 2mg tablets | £1.09 | 30 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Glimepiride 3mg tablets | £1.27 | 30 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Glimepiride 4mg tablets | £1.32 | 30 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 21 Dec 2018 AMARYL — safety-related labeling change
Labeling sections changed: Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 21 Dec 2017 DUETACT — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Combinations containing Glimepiride
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.